Back to top
more

Guardant Health (GH)

(Delayed Data from NSDQ)

$164.92 USD

164.92
1,187,228

+1.74 (1.07%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $164.99 +0.07 (0.04%) 4:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Urmimala Biswas headshot

Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run?

by Urmimala Biswas

Tempus AI rallies in 2025, but a Hold rank and mixed style scores argue for patience until pricing, FDA, and MRD milestones firm up.

Urmimala Biswas headshot

Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook

by Urmimala Biswas

Tempus AI's data engine, MRD buildout and ADLT milestones set the stage for faster growth while profitability metrics turn the corner.

Urmimala Biswas headshot

Tempus AI: Revenue Mix and 2026 Growth Outlook Explained

by Urmimala Biswas

Tempus AI's balanced genomics and data engine is scaling fast as profitability metrics improve and 2026 revenue targets approach the billion-plus mark.

Zacks Equity Research

Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Guardant Health (GH) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

Sridatri Sarkar headshot

TEM Continues to Strengthen Its Genomics Leadership With New Products

by Sridatri Sarkar

Tempus AI advances its genomics push with new assays, CDx progress and plans for whole-genome sequencing to drive future growth.

Zacks Equity Research

Guardant Health (GH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Guardant Health (GH) Reports Q3 Loss, Beats Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of +18.75% and +13.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Sridatri Sarkar headshot

Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals

by Sridatri Sarkar

TEM secures multiple FDA clearances in 2025, boosting its AI-driven diagnostic portfolio across oncology and cardiology.

Sridatri Sarkar headshot

Tempus AI Fuels Growth Through Strategic Biotech Collaborations

by Sridatri Sarkar

TEM expands its AI-driven growth with new collaborations in oncology, neurogenomics, and diagnostic innovation.

Zacks Equity Research

DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute

by Zacks Equity Research

Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.